Literature DB >> 9391187

Calculation of residence times and radiation doses using the standard PC software Excel.

H Herzog1, H Zilken, A Niederbremer, W Friedrich, H W Müller-Gärtner.   

Abstract

We developed a program which aims to facilitate the calculation of radiation doses to single organs and the whole body. IMEDOSE uses Excel to include calculations, graphical displays, and interactions with the user in a single general-purpose PC software tool. To start the procedure the input data are copied into a spreadsheet. They must represent percentage uptake values of several organs derived from measurements in animals or humans. To extrapolate these data up to seven half-lives of the radionuclide, fitting to one or two exponentional functions is included and can be checked by the user. By means of the approximate time-activity information the cumulated activity or residence times are calculated. Finally these data are combined with the absorbed fraction doses (S-values) given by MIRD pamphlet No. 11 to yield radiation doses, the effective dose equivalent and the effective dose. These results are presented in a final table. Interactions are realized with push-buttons and drop-down menus. Calculations use the Visual Basic tool of Excel. In order to test our program, biodistribution data of fluorine-18 fluorodeoxyglucose were taken from the literature (Meija et al., J Nucl Med 1991; 32:699-706). For a 70-kg adult the resulting radiation doses of all target organs listed in MIRD 11 were different from the ICRP 53 values by 1%+/-18% on the average. When the residence times were introduced into MIRDOSE3 (Stabin, J Nucl Med 1996; 37:538-546) the mean difference between our results and those of MIRDOSE3 was -3%+/-6%. Both outcomes indicate the validity of the present approach.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9391187     DOI: 10.1007/s002590050182

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  3 in total

1.  Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-L-tyrosine.

Authors:  Dirk Pauleit; Frank Floeth; Hans Herzog; Kurt Hamacher; Lutz Tellmann; Hans-W Müller; Heinz H Coenen; Karl-J Langen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-15       Impact factor: 9.236

2.  Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.

Authors:  Andreas Helisch; Gregor J Förster; Helmut Reber; Hans-Georg Buchholz; Rudolf Arnold; Burkhard Göke; Matthias M Weber; Bertram Wiedenmann; Stanislas Pauwels; Ulrike Haus; Hakim Bouterfa; Peter Bartenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-03       Impact factor: 9.236

3.  Biodistribution and radiation dosimetry of the A1 adenosine receptor ligand 18F-CPFPX determined from human whole-body PET.

Authors:  Hans Herzog; David Elmenhorst; Oliver Winz; Andreas Bauer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03-29       Impact factor: 9.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.